PREPARATION AND CHARACTERIZATION OF LAFUTIDINE AS IMMEDIATE RELEASE ORAL STRIP USING DIFFERENT TYPE OF WATER-SOLUBLE POLYMER

SABA ABDULHADI JABIR, HALAH TALAAL SULAIMAN

Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq

Email: sabahadee77@yahoo.com

Received: 14 Jul 2018, Revised and Accepted: 11 Aug 2018

ABSTRACT

Objective: The objective of the present study was to design and optimize oral fast dissolving film (OFDF) of practically insoluble drug lafutidine in order to enhance bioavailability and patient compliance especially for a geriatric and unconscious patient who are suffering from difficulty in swallowing.

Methods: The films were prepared by a solvent casting method using low-grade hydroxyl propyl methyl cellulose (HPMC E5), polyvinyl alcohol (PVA), and sodium carboxymethyl cellulose (SCMC) as film forming polymers. Polyethylene glycol 400 (PEG400), propylene glycol (PG) and glycerin were used as a plasticizer to enhance the film forming properties of the polymer. Tween 80 (1% solution) and poloxamer407 were used as a surfactant, citric acid as a saliva stimulating agent, and croscarmellose as a super disintegrant. Films were then tested for both physical (weight variation, thickness, surface pH, drug content) and mechanical (folding endurance, tensile strength, percent elongation, Young’s modulus) characteristics. *In vitro* disintegration, time and drug release profile were also determined for each formula.

Results: Films were found to be satisfactory when evaluated for both physical and mechanical characteristics. The surface pH of all the films was found to be within the range of salivary pH 6.8. The USP dissolution apparatus type II (paddle type) was used for *in vitro* drug release studies. The optimized formulation F13 gave 100% of drug released at 2 min. It also showed satisfactory surface pH (6.2±0.2), drug content (100.1±0.01%), the disintegration time of (7.0±0.5) seconds and the time needed for 80% of medication to be released (T80%) was 0.96 min.

Conclusion: Lafutidine OFDF was formulated using HPMC E5 as film-forming polymer with PEG400 as a plasticizer. Combination of tween80 (1% solution) and poloxamer407 as a surfactant were used in the presence of croscarmellose as a super disintegrant. The chosen OFDF disintegrates within seven seconds, releases the drug rapidly and gives an action.

Keywords: Lafutidine, Oral fast dissolving film, OFDF, Solvent casting method

INTRODUCTION

Oral administration is one of the most crucial routes of administering a drug with high credit to obtain a systemic effect due to its simplicity, comfort ability by producing no pain compared with the systemic administration. However, disadvantages in case of certain oral dosage forms capsules and tablets, such as swallowing problems especially for children, infants and elderly leading to in compliance and disadherence to the treatment [1]. Approximately 35% of the population showed dysphagia and troubles with swallowing also people with hiccups, gagging, sea/motion sickness, and obstruction of the esophagus pathway will be forced to search for other alternatives which favor the systemic drug delivery such as fast-dissolving medication [2].

Oral fast dissolving films (OFDFs) are the most advanced form of an oral solid dosage form, which disintegrate or dissolve within a minute when placed in the mouth without drinking water or chewing. The anatomical composition of the buccal cavity, high blood flow as well as the high permeable nature of the buccal mucosa make using of such dosage forms have quite privileges such as rapid onset, with immediate bioavailability [3].

Oral films are formulated using polymers, plasticizer, flavors, colors, and sweeteners. Hydrophilic polymers are rapidly disintegrated or dissolved in the oral cavity delivering the drug to the systemic circulation that was used in the preparation of OFDFs. Plasticizer helps to enhance the flexibility and reduces the brittleness of the strip [4].

Lafutidine is a new H2-receptor antagonist, after absorption in the small intestine, it reaches gastric cell by the systemic circulation, then directly and quickly binds to gastric cell H2-receptor resulting in promote inhibition of gastric acid secretion. The drug is predominantly metabolized in the liver by microsomal enzyme CYP3A4 and CYP2D6. Its major metabolites are hydroxylated lafutidine and sulfonyl lafutidine [5, 6]. Its maximum plasma concentration of 133.9±8.1 (ng/ml) will be reached at time of (1.84±0.334) h [7]. It has a biological half-life of 1.92 h [8]. Lafutidine has a receptor binding affinity which is 2-80 times higher than other representative H2-receptor antagonists (e.g. famotidine, ranitidine and cimetidine) [9].

Lafutidine exerts gastroprotective effects independent of its antisecretory action by increasing intracellular Ca2+ ion concentration in endothelial cell that provokes the release of neurotransmitters CGRP which stimulate nitric oxide(NO) production in endothelial cell. Where NO plays a role in the control of gastric mucosal blood flow by vasodilatation within the gastric microvasculature [10].

Lafutidine has been found to significantly increase plasma somatostatin level at (0.3-2) h after administration where somatostatin inhibits gastric acid secretion by acting directly on its receptor on a parietal cell and indirectly by decreasing gastrin from antral G cell [9].

The aim of this study was to formulate and *in vitro* evaluate an OFDF of practically insoluble lafutidine to enhance its solubility, improve compliance and bioavailability as well as to produce an immediate release action of lafutidine from the film for an efficient management of gastric ulcers, duodenal ulcers and gastric mucosal lesions combined with acute or chronic gastritis.

MATERIALS AND METHODS

Material

Lafutidine and Poloxamer 407 were purchased from Hangzhou Hyper Chemicals Limited, Zhejiang; China. HPMC E5, PVA, and SCMC were supplied from Samarra Drug Industry (SDI) as a gift. Glycerin and PEG400 were purchased from Fluka Chemical AG, Switzerland. PG was purchased from Evans Medical Ltd, Liverpool, England. All
other chemicals and solvents were of analytical reagent grade, and deionized water also was used in this study.

Method

Construction of calibration curve
Calibration curve for lafutidine in phosphate buffers (pH 6.8) were made by preparing serial dilutions of the drug from a stock solution (0.48 mg/ml). Samples (9.6, 19.2, 38.4, 48, 57.6 and 76.8 µg/ml) were then analyzed spectrophotometrically for lafutidine at its λmax (273 nm) [11].

Method for preparation of lafutidine OFDF
Fourteen formulas were prepared (F1-F14) as listed in table 1 by using the solvent casting method; every film of about 4 cm² area must contain 10 mg of lafutidine. The size and number of films that formulated for every group designed as the following:

The dose of the drug to be incorporated in each 4 cm² film = 10 mg of lafutidine.

The diameter of petri dish is 11 cm, so that the radius = 5.5 cm.

Area of Petri dish = π r²; 3.14 × (5.5 cm)² = 94.985 cm² approximately 95 cm².

A number of 4 cm² films obtained from the main film =95 cm² + 4 cm² = 23.75 films approximately 24 films each with area 4 cm².

The amount of lafutidine should be incorporated in the area considered is calculated as follow:

24 film × 10 mg=240 mg.

The OFDFs of lafutidine were prepared by a solvent casting method. The considered quantity of film-forming polymer was dissolved in 20 ml of solvent (distilled water) with constant stirring using a magnetic stirrer for two h to form a homogenous polymeric solution. To this polymeric solution, a suitable amount of plasticizer was added with continuous stirring for another one h. In another beaker, the drug was dissolved in 8 ml mixture of (0.1N HCl and 1% tween80 solution) to form a clear solution; then the volume was completed to 10 ml with distilled water. Salva stimulating agent, sweetener and superdisintegrant were added to the drug solution. The two solutions (polymer and drug) were mixed using a magnetic stirrer for one h; then it was kept in a sonicator for degassing. The bubble-free solution was cast on to a petri dish with a diameter of 11 cm² and kept in hot air oven (60°C) overnight. The dried film was then removed and cut into the desired shape and size (2 cm × 2 cm) for the intended application. Cuts or defectiveness were omitted from the study [12].

Table 1: Composition of lafutidine oral films formulas

| Ingredients present in each film (mg) | F1   | F2   | F3   | F4   | F5   | F6   | F7   | F8   | F9   | F10  | F11  | F12  | F13  | F14  |
|---------------------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| Lafutidine                            | 10   | 10   | 10   | 10   | 10   | 10   | 10   | 10   | 10   | 10   | 10   | 10   | 10   | 10   |
| HPMC E5                               | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   |
| PVA                                   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   | 25   |
| SCMC                                   | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  |
| PEG 400                               | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  |
| Glycerin                               | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  | 7.5  |
| Tween 80                              | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  | 1.6  |
| Poloxamer407                           | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  |
| Croscarmellose                         | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  |
| Citric acid                            | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  |
| Vanilla                                | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  |
| Sodium saccharin                       | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  | 1.5  |

Evaluation of lafutidine OFDF

Physical characterization of the prepared films
Physical characteristics such as color, thickness, brittleness, peeling ability, transparency, surface smoothness, tack property and film-forming capacity can be carried out by visual inspection for all the above characteristics [13].

Weight variation
The uniformity of the film formed was confirmed by weight variation test. Ten randomly selected films from each patch (each of 2 cm × 2 cm) were weighed individually and matched with the mean weight for deviation [14].

Thickness measurements
Digiomatic and Vernier Caliper was used to measure the film thicknesses. Each film was measured at five positions (central and the four corners) the mean thickness was calculated. This test was performed on six films of each formulation and mean±S.D calculated [15].

Drug content uniformity
Drug content was determined by taking three films from each formulation patch randomly and weighed individually. Each film was dissolved in 5 ml of methanol, sonication; the volume was completed to 10 ml with distilled water then filtered through 0.45µm filter syring. Using 100 ml volumetric flask, 1 ml of the filtrate was diluted with distilled water to the mark and analyzed spectrophotometrically at λmax (279 nm). The average drug content was calculated [16].

Determination of surface pH
Surface pH determination is important to investigate any side effects when using the OFDFs in vivo, due to the irritation of the mucosal membrane of an oral cavity by acidic or basic pH. OFDFs pH value was measured by dissolving one film in 2 ml of distilled water and the solution’s pH was determined using Schott Gerate pH-meter.

Different pH value will be expected because of the fact of using a different film forming polymers in the formulation of OFDFs along with the drug [17].

Folding endurance
The number of time the film is folded without breaking is known as the folding endurance value. Folding endurance is measured by manual repeated folding of the film at the same place till it broke. A film of an area of 4 cm² was subjected to folding endurance by folding the film at the same place several times repeatedly until a visible crack was observed and the average values were calculated and reported. The value of folding endurance of more than 300 indicating that the formulation is good, tough and flexible [18].

Tensile strength
Define as the maximum value of forces applied on the film to breaks down. Tensometer was used to measure the tensile strength by holding a film of 5 cm × 2 cm (which must be pure from air bubbles or any physical defectiveness and cut as dumbbell-shaped) longitudinally in it, then it was drawn at a level of 10 mm/min. Mathematically measurement of the tensile strength by dividing the applied force at which the film was broken on the cross-section area
of it, as shown in the following equation. Mega Pascal (MPa) is a unit of tensile strength [19].

\[
\text{Tensile Strength} = \frac{\text{Load to Break}}{\text{Width} \times \text{Thickness}} \times 100
\]

Percentage elongation

The deformation of the film divided by the original dimension of it known as a strain which is referred to the stretches of the sample when stress is applied. Elongation related to the stretching of the film sample when stress is applied. As the plasticizer concentration increases the elongation of the film increases too. Percentage elongation (\%E) was calculated by measuring the increase in the length of the film after tensile strength measurement by using the following equation [20].

\[
\text{Percentage Elongation (\%E)} = \left( \frac{\text{Final length} - \text{Initial length}}{\text{Initial length}} \right) \times 100
\]

Young’s modulus

Measuring the stiffness of the film is referred to young’s modulus or elastic modulus. It is represented as the ratio of applied stress over strain in the region of elastic deformation as follows:

\[
\text{Young’s modulus} = \text{Elongation} \times \text{Young’s modulus}
\]

In vitro disintegration time (DT)

The time at which the OFDF starts to break down or disintegrate is known as the DT. It was measured by a petri dish method. The test was done by taking three films from each formula then in a petri dish 2 ml of distilled water was adding for each film, it was shaken continuously, then measure the time at which the OFDF starts to break down or disintegrate. It was done in triplicate for all the formulations [23].

In vitro dissolution study

The dissolution study was carried out using USP type II (paddle apparatus) with 200 ml of phosphate buffer pH 6.8 as a dissolution medium maintained at 37±0.5°C. The medium was stirred at 50 rpm for a period of 20 min. Samples were withdrawn by using a syringe fitted with a microfilter (0.45 μm) at regular intervals (1, 2, 3, 4, 5, 10, 15 and 20 min) replaced with fresh medium in order to maintain sink conditions. Samples were analyzed spectrophotometrically at 273 nm for the drug content. Cumulative percent of lafutidine released was calculated and plotted against time [24].

Statistical analysis

The results of the experiments are given as a mean of triplicate samples ± standard deviation and were analyzed according to the one way analysis of variance (ANOVA) at the level of (P≤0.05) to determine if the changes in the applied factors are statistically significant at level of (P≤0.05) and non-significant at level of (P>0.05).

RESULTS AND DISCUSSION

Visual inspection

All the prepared OFDFs which contain HPMC ES, PVA, and SCMC showed homogenous and smooth surface properties, where as HPMC and PVA films were transparent, colorless, thin and soft while those prepared from SCMC were thin, soft, colorless and semi-transparent.

Weight variation

The average weights for all the prepared formulations were uniform and fit to the referred values as shown in table 2, so the strategy utilized for the preparation of films is reproducible and give films of uniform weight. Digital balance was used to determine the weight of the films, all show consistency.

Thickness

The average thickness values of films for all formulas were shown in table 2. The accepted range of content uniformity labeled in BP is ±0.03. As shown in table 2 the thickness was found to vary between (0.08±0.02) to (0.16±0.01) mm. A very low standard deviation value is indicating that the method used for the formulation is reproducible and give films of uniform thickness, hence dosage accuracy in each film can be ensured.

Drug content

The formulated lafutidine films showed an acceptable quantity of medicament ranged from (96.8±0.4 %) to (102±0.2 %) as shown in table 2. The accepted range of content uniformity labeled in BP is ranged from 85 % to 115 %. The results is obeying this range, which indicating that the solvent casting method used in preparing of lafutidine OFDFs is very efficient. So the drug was spread uniformly throughout the 4 cm² constant area of the films.

Surface pH measurement

All the prepared films showed an acceptable surface pH value (6.1±0.2) to (6.5±0.1) as viewed in table 2 when compared to the pH of oral mucosa indicating that it does not cause an irritation to it.

Percent moisture absorb (PMA)

Moisture uptake holds a critical investigation on drug stability. All the reported values of moisture uptake are listed in the table 2. It was detected that all the polymers were hydrophilic in nature and the moisture absorb values ranged from (1.0±0.6 %) to (9.4±0.1%).

| Formula code | Weight variation (mg) *** | Thickness (mm) ** | Drug content* | Surface PH* | In vitro DT(s) * | PMA* |
|--------------|--------------------------|------------------|--------------|-------------|-----------------|------|
| F1           | 5.6±0.01                 | 0.08±0.02        | 100.1±0.1    | 6.3±0.5     | 8±0.5           | 3.80±0.55 |
| F2           | 5.9±0.01                 | 0.11±0.02        | 99.6±0.2     | 6.2±0.3     | 10±0.2           | 4.0±0.6  |
| F3           | 5.1±0.02                 | 0.12±0.02        | 98.2±0.5     | 6.2±0.2     | 16±0.4           | 6.6±0.32 |
| F4           | 7.1±0.04                 | 0.16±0.01        | 100.5±0.2    | 6.2±0.3     | 300±0.6          | 9.4±0.1  |
| F6           | 6.1±0.06                 | 0.13±0.02        | 100±1        | 6.1±0.1     | 10±0.4           | 5.8±0.25 |
| F7           | 6.9±0.05                 | 0.12±0.04        | 101±0.2      | 6.2±0.3     | 78±0.1           | 7.2±0.2  |
| F8           | 5.3±0.02                 | 0.11±0.01        | 99.9±0.1     | 6.3±0.5     | 75±0.5           | 4.4±0.3  |
| F9           | 5.6±0.06                 | 0.09±0.02        | 98.1±0.2     | 6.2±0.4     | 10±0.5           | 4.2±0.32 |
| F10          | 5.2±0.02                 | 0.08±0.05        | 102±0.2      | 6.0±0.5     | 12±0.4           | 5.1±0.6  |
| F11          | 6.2±0.05                 | 0.09±0.02        | 96±0.4       | 6.5±0.1     | 15±0.5           | 6.0±0.45 |
| F12          | 5.2±0.06                 | 0.09±0.03        | 101±0.1      | 6.2±0.4     | 10±0.2           | 5.0±0.13 |
| F13          | 5.3±0.01                 | 0.09±0.02        | 98.6±0.4     | 6.3±0.1     | 11±0.2           | 4.8±0.6  |
| F14          | 5.1±0.01                 | 0.08±0.01        | 98.6±0.2     | 6.3±0.1     | 9±0.2            | 4.4±0.3  |

All values were calculated as mean±SD, * n=3, ** n=6, *** n=10
Table 3: Mechanical properties of lafutidine OFDFs formulas

| Formula code | Folding endurance | Tensile strength | Percent of elongation | Young's modulus. |
|--------------|------------------|------------------|----------------------|-----------------|
| F1           | 450±5.5          | 6.5±0.2          | 21.1±0.2             | 105±0.3         |
| F2           | 500±6.5          | 16±0.1           | 28.3±0.6             | 110.6±0.4       |
| F3           | 800±6.4          | 19±0.12          | 30.1±0.5             | 116±0.8         |
| F4           | 600±10           | 22±0.8           | 28±0.8               | 120±2.5         |
| F5           | 800±8.0          | 18±0.5           | 26±0.5               | 116±3.1         |
| F6           | 1200±12          | 20±0.3           | 32±0.6               | 118±1.5         |
| F7           | 600±3.4          | 4.6±0.4          | 25.5±0.3             | 116±2.1         |
| F8           | 400±2.6          | 6.1±0.3          | 19.8±0.8             | 102±0.2         |
| F9           | 150±1.5          | 5.2±0.4          | 14.2±0.6             | 115±0.5         |
| F10          | 380±2.5          | 7.6±0.5          | 18.5±0.3             | 112.5±0.5       |
| F11          | 400±3.5          | 8.2±0.7          | 17.4±0.2             | 115.4±0.3       |
| F12          | 370±1.5          | 4.4±0.2          | 18.6±0.2             | 88±2.1          |
| F13          | 359±2.0          | 5.4±0.1          | 18.5±0.6             | 86±0.5          |
| F14          | 480±0.6          | 4.4±0.2          | 17.5±0.6             | 89±0.6          |

All values were calculated as mean±SD, n=3

Effect of different types of polymers

As shown in table 1 formulas (F1, F2 and F3) were utilized to study the effect of polymer type (HPMC E5, PVA, and SCMC) with concentration (50% w/w of the total dry weight) on the physical and mechanical properties of the prepared lafutidine OFDFs as well as their effect on the drug release profile.

According to the results obtained, potential differences could be investigated between the three polymers without changing their ratio in the prepared film, also variation in the DT and mechanical characteristics could be identified in order to select the polymer that has the best film forming properties. The mechanical properties of OFDFs are very essential since it related to their stability during storage, shipping and packaging.

A high % E value shows that the film is flexible and tough. Tensile strength has been utilized as a marker of the general mechanical prevalence of the film. Folding endurance test results indicated that the films would maintain the integrity with buccal mucosa when applied and has good plasticity. This makes the system acceptable for movement of the mouth, indicating good strength and elasticity. The selected OFDFs must have reasonable tensile strength, high % E, low young's modulus, short DT and a high percent of drug release.

The results in the table 2 showed that the DT of formulas F1, F2 and F3 were 8, 10 and 16 s respectively, this indicates that F1 gave the shortest DT in the mouth compared to the other formulas [25]. Except for PVA the retardation in disintegration is due to the swelling property of this polymer which makes a gel-like layer on the surface of the film upon contact with aqueous media leads to preventing penetration of water to the film, this swelling property increased with increasing the polymer concentration [26].

So different film-forming polymers gave different DT value as shown in the fig. 1:

Fig. 1: In vitro disintegration time of different film-forming polymers, (mean±SD, n=3)

As expressed in table 3 in which the mechanical properties of OFDFs are listed, the film prepared with HPMC E5 (F1) as film-forming polymer gave satisfactory % E (21.1±0.2), excellent folding endurance value (450±5.5), with low value of young's modulus (105±0.3) and the tensile strength, is about (6.5±0.2), these outcomes were in concurrence with those that reported by Tamer et al. [27].

Formula F2 prepared with PVA as film-forming polymer exhibited a high %E (28.3±0.6), and good folding endurance (500±4.5). High values of young's modulus and tensile strength were (110.6±0.4) and (16±0.1) respectively while the films prepared with SCMC as film forming polymer exerts higher values of folding endurance (800±6.4), %E (30.1±0.5), Young's modulus (11±0.8) and tensile strength (19±0.12) as shown in table 3. These findings agreed with the results reported by Chinnala et al. [28].

Fig. 2 showed the dissolution profile of formulas (F1, F2 and F3), it was clear that the cumulative percentage of lafutidine released from the investigated polymers would be as follow: F1>F2>F3.

The difference in dissolution may be attributed to the difference in composition of film-forming materials [25].
The values of T80% (time needed for 80% of medication to be released) for F1, F2 and F3 were 1.68, 1.9 and 1.87, min respectively, as well as the values of % D2 min (percentage medication released in 2 min) were 95%, 84% and 85.4% respectively as listed in table 4.

Table 4: *In vitro* dissolution parameters from the prepared OFDFs (F1, F2 and F3)

| Formula | T80% (min) | D2 min (%) |
|---------|------------|------------|
| F1      | 1.68±0.1   | 95±0.2     |
| F2      | 1.9±0.15   | 84±0.25    |
| F3      | 1.87±0.2   | 85.4±0.4   |

All values were calculated as mean±SD, n=3, from all these results we found that HPMC E5 (F1) had the best physical, mechanical properties and drug release profile than the other film forming polymers.

**Effect of selected polymer (HPMC E5) combination**

According to the physical, mechanical properties, and the drug release profile, HPMC E5 (F1) was selected as an optimized suitable polymer for preparing of lafutidine OFDF.

Formulas F4, F5 (HPMC E5 with PVA in a ratio of 1:1 and 1:0.5 respectively) and F6 (HPMC E5 with SCMC in 1: 0.5 ratio ) were further evaluated to get an optimum suitable polymer combination by studying their physical, mechanical and the dissolution profile parameters.

Table 2 revealed that there is a significantly (*p* ≤ 0.05) increased in the *in vitro* DT of the formulated OFDFs with increasing the ratio of polymer combination with HPMC E5 from F4>F5>F6.

Fig. 3 showed that films containing a high concentration of polymer (HPMC E5 with PVA) resulted in a thicker gel upon contact with the medium, leading to longer DT except for SCMC with HPMC E5 which is more water soluble than PVA in the same ratio [29]. This was agreed with the result obtained from metoprolol tartrate strips and lamotrigine fast dissolving films [30, 31].
The outcomes listed in table 3, indicate that film with high value of tensile strength result from increasing the polymer concentration is due to the fact that densely packed chains of HPMC produced from polymer combination make the film need more force to breaks [32]. These findings agreed with the results obtained by Kazan et al. [33]. Also high % E and higher folding endurance of the films were detected upon a combination of polymers as shown in table 3, which is due to increase in the elasticity nature of the polymer [28]. Similar observations were found by Trivedi J et al. [34].

Table 5 shows that formula (F1) has the highest T2 min (95%) and the lowest T80% (1.68 min) indicating that F1 which formulated only with HPMC E5 as a film-forming polymer gave fastest dissolution rate compared with the F4, F5 and F6 which formulated using different ratio of polymer combination with HPMC E5.

Table 5: In vitro dissolution parameters from the prepared OFDFs (F1, F4, F5, and F6)

| Formula code | T80% (min) | D2 min (%) |
|--------------|-----------|------------|
| F1           | 1.68±0.5  | 95±0.2     |
| F4           | 6.9±0.5   | 70.6±0.2   |
| F5           | 2.9±0.25  | 78±0.55    |
| F6           | 2.94±0.3  | 76.3±1.25  |

All values were calculated as mean±SD, n=3

From the dissolution parameters that shown in table 5 for the formulas (F1, F4, F5 and F6) prepared with a different combination ratio of each polymers (PVA, SCMC) with HPMC E5, it was clear that the dissolution rate of lafutidine reduces significantly (p<0.05) as the ratio of polymer combination with HPMC E5 increases from 1: zero in formula (F1) to 1:1 in formula (F4) as shown in fig. 4, this result may be due to the fact that higher concentration of polymers, produce a high consistency gel layer created by close interaction between the particles resulting in a diminished movement of medication particles in swollen lattices, which prompt a decline in dissolution rate [32].

The percentage of lafutidine released from the investigated polymer combination would be higher for formula as follow: F1>F6>F5>F4. Therefore, F1 which contain only HPMC E5 (50 % w/w) with 0% of other polymers was considered as the best polymer chosen for the design of the subsequent formulas through the study.

Effect of the plasticizer type

Formulas (F1, F10, and F11) were employed to study the effect of different plasticizer types at a certain concentration 30% w/w (PEG 400, glycerin, and PG) on the physical and mechanical properties of the prepared lafutidine OFDFs as well as their effect on the drug release profile.

The results indicate that no significant changes (p>0.05) were shown on the in vitro DT of the OFDF upon changing of plasticizer type as shown in fig. 5, this may be due to the fact that penetration of fluid into the film was facilitated by the three types of plasticizer since the densely packed chains of HPMC were altered by the plasticizer through forming a polymer structure possess more pores and less densely that breaks at lower force, resulting in faster disintegration of the film [35].

Higher value of folding endurance was shown for PEG 400 containing formula compared with the others. On the other hand, soft and tough film was made with glycerin while PG produced the patchy and sticky film. At the same time, film plasticized with PEG 400 exhibited good physical and mechanical properties such as tensile strength and %E as shown in table 3. These observations are in accordance with Ali MS et al. [36] and Choudhary et al. [37]. So PEG400 was selected for further study for suitability in films formulation.

T80% and %D2 min from the formulated films (F1, F10 and F11) are listed below in table 6.

The release profile of lafutidine from formulas (F1, F10 and F11) which contain 30% w/w of (PEG 400, glycerin and PG) respectively
is displayed in fig. 6. No significant change (p>0.05) on the dissolution profile was seen by changing the plasticizer type because all the three plasticizers are water soluble, and they will diffuse out from the films in watery media making void spaces in the film through which diffusion of liquid happened enabling film breaking down leading to improve release profile of drug [38].

![Fig. 5: In vitro disintegration time in seconds of formulas prepared with different types of plasticizer, (mean±SD, n=3)](image_url)

**Table 6: In vitro dissolution parameters from the prepared OFDFs (F1, F10 and F11)**

| Formula code | T80% (min) | D2 min (%) |
|--------------|------------|------------|
| F1           | 1.68±0.5   | 95±0.2     |
| F10          | 1.86±0.2   | 86±0.55    |
| F11          | 1.8±0.15   | 90±0.8     |

All values were calculated as mean±SD, n=3

![Fig. 6: Cumulative percentage of lafutidine released from formulas prepared with different types of plasticizer in phosphate buffer (pH 6.8) at 37 °C, (mean±SD, n=3)](image_url)

**Effect of the selected plasticizer concentration**

Formulas (F1, F7, F8 and F9) were used to study the effect of different concentrations of selected plasticizer PEG400 (30, 34, 24 and 16 % w/w of the total film weight) on the in vitro DT, mechanical properties and the drug release profile of the oral film. Formulas (F1, F7, F8 and F9) showed that increasing the concentration of the selected plasticizer (PEG400) accompanied with decreasing in the DT as shown in fig. 7, this is due to the effect of PEG 400 as co-solvent which increases the solubility of non-polar, hydrophobic compounds by reducing the water squeezing out of them [39].

![Diagram](image_url)
The mechanical properties of formulas (F1, F7, F8 and F9) were shown in table 3, which illustrated that as the plasticizer concentration increased the young's modulus and the tensile strength decreased. This is due to the fact that the intermolecular forces between polymer chains weakened upon increasing the concentration of plasticizer thus the rigidity of the three-dimensional structure formed upon drying decreased [27].

Moreover, the %E was increased with increasing plasticizer concentration. These results can be explained by the (lubricity theory) which states that the plasticizers act as an interior emollient and enhance movement of the polymer chains [40].

The release profile of lafutidine from formulas (F1, F7, F8 and F9) which contain 30, 34, 24 and 16% w/w of PEG 400 respectively were shown in fig. 8, it was observed that as the concentration PEG 400 increased the drug release rate significantly increased (p<0.05) this was explained by the role of PEG 400 as a facilitating dissolution agent [41].

Table 7: In vitro dissolution parameters from the prepared OFDFs (F1, F7, F8 and F9)

| Formula code | T80% (min) | D2 min (%) |
|--------------|------------|------------|
| F1           | 1.68±0.5   | 95±0.2     |
| F7           | 1.95±0.3   | 82.7±0.8   |
| F8           | 2.93±0.25  | 70±0.65    |
| F9           | 3.9±0.35   | 64±0.4     |

All values were calculated as mean±SD, n=3, from the above results concerning physical, mechanical evaluations and release profile of the prepared OFDFs using different plasticizer types and concentrations. F1 will be subjected for the forward study.
Effect of surfactant type and combination

Formulas (F1, F12 and F13) were used to study the effect of different types of surfactant (tween80, poloxamer407 and combination of both) on the in vitro DT, mechanical properties and the drug release profile of the OFDFs.

Fig. 9 showed that the DT is significantly affected (p<0.05) by the type of surfactant so the best result (7 s) was obtained from F13 upon a combination of the two types of surfactants (tween80 and poloxamer407) [42].

The mechanical properties of formulas (F1, F12 and F13) were listed in table 3, all the values of folding endurance, tensile strength, %E and young's modulus were within the range of accepted OFDFs.

The release profile of lafutidine from formulas F1, F12 and F13 which contain tween80, poloxamer407 and combination of both surfactants, respectively was shown in fig. 10. It was observed that combination of surfactants (F13) significantly (p<0.05) increased the release of the drug from OFDFs, this is due to the additive effect of the water-soluble surfactant (poloxamer 407) which increases the solubility of the drug with a hydrophilic surfactant (tween80) that acts by decreasing surface tension and increasing wettability of the drug [12, 43].

The T80% and %D2 min values for formulas (F1, F12, and F13) were illustrated below in table 8.

Table 8: In vitro dissolution parameters from the prepared OFDFs (F1, F12 and F13)

| Formula code | T80%(min) | D2 min (%) |
|--------------|-----------|------------|
| F1           | 1.68±0.5  | 95±0.2     |
| F12          | 3.7±0.3   | 64.6±0.8   |
| F13          | 0.96±0.25 | 100±0.1    |

All values were calculated as mean±SD, n=3, Formula (F13) was chosen as the best one and can be further evaluated throughout the study depending on the previous outcomes that gave shorter DT, lower T80%, maximum D2 min and satisfactory mechanical properties.

Effect of superdisintegrant

Formulas F13 and F14 listed in table 1 which contain croscarmellose 5% and 0% respectively were allowed to study the DT and the release profile.

Fig. 11 showed that croscarmellose significantly decreased (p<0.05) the DT of the OFDFs, this owing to the great capillary action of the superdisintegrant which quickly absorbs water into the film, swelling then giving a fast disintegration.
Fig. 11: *In vitro* disintegration time in seconds of formulas prepared with and without croscarmellose as a super disintegrant, (mean±SD, n=3)

Fig. 12 showed the effect of croscarmellose on the release profile of lafutidine from formulas F13 (with superdisintegrant) and F14 (without superdisintegrant). Faster release (p<0.05) was observed for F13 in comparison with F14 which is due to the highly porous structure of the superdisintegrant particles, help them to wick the liquid, swelling then break down and release of the drug [44, 45].

Fig. 12: Cumulative percentage of lafutidine released from formulas prepared with and without croscarmellose as superdisintegrant in phosphate buffer (pH 6.8) at 37 °C, (mean±SD, n=3)

The $T_{80\%}$ and $D_{2 \text{ min}}$ values for formulas (F13 and F14) were illustrated in table 9 below.

Table 9: *In vitro* dissolution parameters from the prepared OFDFs (F13 and F14)

| Formula code | $T_{80\%}$ (min) | $D_{2 \text{ min}}$ (%) |
|--------------|------------------|------------------------|
| F13          | 0.96±0.25        | 100±0.1                |
| F14          | 2.13±0.4         | 75±0.6                 |

All values were calculated as mean±SD, n=3. From the previous results F13 which shown below in the fig. 13 was selected as the best formula for preparing of lafutidine as OFDF.

Fig. 13: The best-selected formula F13
CONCLUSION
According to the results obtained, HPMC E5 showed the shortest in vitro DT accompanied with acceptable mechanical properties and dissolution behavior. PEG400 was the best plasticizer as it showed an improvement in the mechanical and physical characteristics of the lafutidine ODFs. Formula (F13) which composed from 50% w/w HPMC E5 as a film forming polymer, 30% PEG400 as a plasticizer, 3.2% of each poloxamer 407 and tween 80 as surfactants, finally 3% croscarmellose sodium as superdisintegrant. This is regarded as an optimized formula with a low DT (7±0.5 s) and 80% of drug released within (0.96 min).

When lafutidine administered in the form of ODFs will be a potential novel drug dosage form for geriatric by providing faster release and better patient compliance.

ACKNOWLEDGMENT
We are very thankful to the research and material department/Ministry of Science and Technology, College of Pharmacy/University of Baghdad, Iraq, for providing the necessary facilities that help to complete our work.

AUTHORS CONTRIBUTIONS
All the authors have contributed equally

CONFLICTS OF INTERESTS
Declared none

REFERENCES
1. Patel D, Patel M, Upadhyay P, Shah N, Shaha S. A review on mouth dissolving film. J Pharm Sci Bio Res 2015;5:266-73.
2. Nair V, Saudagar RB, Gondkar SB. A review on fast dissolving sublingual films for systemic drug delivery. World J Pharm Sci 2015;4:52-61.
3. Banarjee T, Ansari VA, Singh S, Mohmood T, Akhtar J. A review on fast dissolving films for buccal delivery of low doses drugs. Int J Leg Stu Res 2015;1:117-23.
4. Singh G, Saini S, Gill NS. Oral fast dissolving films: an innovative drug delivery system. Int J Univ Pharm Bio Sci 2014;3:163-77.
5. Moorkoth S, Kumar S, Pai A, Kamath V. Stability is indicating analytical method development and validation of lafutidine in tablet dosage form by RP-HPLC. Min J Pharm Med Sci 2013;2:18-21.
6. Reddy MB, Hari B. Determination of lafutidine through oxidative coupling reaction in bulk sample and dosage forms-a new approach. Int J Pharm Sci Res 2016;6:2626-30.
7. Ikawa K, Shimatani T, Hayato S, Morikawa N, Tazuma S. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine. Biol Pharm Bull 2007;30:1003-6.
8. Yamagishi H, Koike T, Ohara S, Horii T, Kikuchi R, Kobayashi S, et al. Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole. World J Gastroenterol 2008;14:2406-10.
9. Dewan B, Chimata R. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gas trointestinal Tumour Ther 2011;4:112-9.
10. Onodera S, Shibata H, Tanaka M, Inaba N, Yamauchi T, Ohnishi T. Development and evaluation of fast dissolving oral films of mirtazapine. J Pharm Innov 2013;8:316-21.
11. Preis M, Pein M, Gudrey V, Roy SD, Reddy PV. Formulation and evaluation of fast dissolving oral films of zolmitriptan by natural polymers. Int J Pharm Investig 2014;4:57-61.
12. Reddy AA, Kamal BA. Formulation and in vitro evaluation of ketotifen fumarate oral strips. Int J Chem Tech Res 2012;4:293-317.
13. Tomar A, Sharma K. Formulation, and evaluation of fast dissolving film of diclofenac as a potential route of buccal delivery. J Drug Res Dev 2011;2:408-17.
14. Tamer MA, Abd-El Hamid SHN, Ahmed B. Formulation and in vitro evaluation of bromocryptine mylsylate as fast dissolving oral film. Int J Appl Pharm Sci 2018;10:7-20.
15. Raju S, Reddy PS, Kumar VA, Deepthi A, Reddy KS, Reddy PM, et al. Flash release oral films of metoloxan and hydrochloride for pediatric use: formulation and in vitro evaluation. J Chem Pharm Res 2011;3:636-46.
16. Jadhav K, Dhamecha D, Tate A, Tambe H, Patil MB. Application of UV spectrometric method for easy and rapid estimation of lafutidine in bulk and pharmaceutical formulation. Pharm Methods 2011;2:264-7.
17. Sultana F, Arafat M, Pathan SI. Preparation and evaluation of fast dissolving oral thin film of caffeine. Int J Pharm Biol Sci 2013;3:153-61.
18. Pathan A, Gupta MK, Jain NK, Dubey A, Agrawal A. Formulation and evaluation of fast dissolving oral film of promethazine hydrochloride using a different surfactant. J Inno Pharm Sci Bio 2016;3:74-84.
19. Maheswari KM, Devineni PK, Deekonda S, Shah S, Uppala NP, Nalluri BN. Development and evaluation of mouth dissolving films of amiodipine besylate for enhanced therapeutic efficacy. J Pharm Innov 2013;3:1-10.
20. Nalluri BN, Sravani B, Anusha VS, Srikumarihini R, Maheswari KM. Development and evaluation of mouth dissolving films of sumatriptan succinate for better therapeutic efficacy. J Appl Pharm Sci 2013;3:316-21.
21. Vijayakumar S, Gavaskar B. Overview on fast dissolving films. Int J Pharm Pharm Sci 2010;2:293-317.
22. Remidi T, Prasanna K, Mohanty D, Spandana M, Ratnaparam S. Formulation and in vitro evaluation of oral thin film of mirtazapine. Int J Adv Pharm Sci 2014;2:844-9.
23. Reis B, Reis M, Breitkreit J. Development of a taste-masked orodispersible film containing dimenhydrinate. Pharmaceuticals 2012;4:551-62.
24. Geddy V, Roy SD, Reddy PV. Formulation and evaluation of fast dissolving oral films of zolmitriptan by natural polymers. Int J Adv Pharm Sci 2014;5:57-67.
25. Radhi AA, Kamal BA. Formulation and in vitro evaluation of ketotifen fumarate oral strips. Int J Sci-Tech 2012;7:53-63.
26. Tomar A, Sharma K. Formulation, and evaluation of fast dissolving film of diclofenac as a potential route of buccal delivery. J Drug Res Dev 2011;2:408-17.
27. Tamer MA, Abd-Al Hamid SHN, Ahmed B. Formulation and in vitro evaluation of bromocryptine mylsylate as fast dissolving oral film. Int J Appl Pharm Sci 2018;10:7-20.
28. Chinnala KM, Panigrahy RN, Banu R, Sravanthi B. Formulation and evaluation of mouth dissolving films containing tizanidine hydrochloride. Int J Pharm Res Health Sci 2015;3:621-623.
29. Prabhu P, Malli R, Koland M, Vijaynarayana K, D’Souza U, Harish N, et al. Formulation and evaluation of fast dissolving films of levocitritazine dihydrochloride. Int J Pharm Investig 2011;1:99-104.
30. Mammat GS, Milind LS, Santosh P, Diouza J. Fast dissolving HPMC E5 based oral film for rapid absorption of metoprolol tartrate. Eur J Pharm Med Res 2014;1:75-91.
31. Duddayya H, Patil SS, Sree GR, Waseem H, Udapi RH. Design and in vitro evaluation of fast dissolving films containing HP & CD inclusion complexes of lamotrigine. J Drug Delivery Ther 2014;4:99-106.
32. Sapkal NP, Kilor VA, Daud AS, Bonde MN. Development of fast dissolving oral thin films of ambroclor hydrochloride: effect of formulation variables. Int J Adv Pharm Res 2011;2:102-9.
33. Kaza R, Elevate PR, Ravou N. Design, and characterization of fast dissolving films of valsartan. Turkish J Pharm Sci 2014;11:175-84.
34. Trivedi J, Patel J, Patel U. Formulation development and evaluation of fast dissolving film of cinnarizine. Int J Pharm Bio Sci 2014;5:639-52.
35. Salman ZD, Marieke NA, Alabassi MG, Ghaerem MM. In vitro/in vivo evaluation and bioavailability study of amitriptyline hydrochloride from the optimized oral fast dissolving films. UK J Pharm Bio Sci 2014;2:32-42.
36. Ali MS, Vijendar C, Kumar S, Krishnaveeni J. Formulation and evaluation of fast dissolving oral films of dizezapam. J Pharmacovigilance 2016;4:210-5.
37. Choudhary DR, Patel VA, Chhalotiya UK, Patel HV, Kundawala AJ. Formulation and evaluation of fast dissolving film of...
levocetirizine dihydrochloride using different grades of methocel. J Pharm Res 2011;4:2919-24.
38. Abd-Alhammid SN, Saleeh HH. Formulation and evaluation of flurbiprofen oral film. Iraqi J Pharm Sci 2014;23:53-9.
39. Jadhav YG, Gałgate UC, Chaudhari PD. Challenges in formulation development of fast dissolving oral film. Ind Am J Pharm Res 2013;3:6391-407.
40. Chauhan SS, Lin S, Madan PL. Preparation and evaluation of nicotine hydrogen tartrate fast dissolving films for smoking cessation. Asian J Pharm Sci 2012;7:181-92.
41. Bala R, Sharma SH. Formulation optimization and evaluation of fast dissolving film of aprepitant by using the design of the experiment. Bull Fac Pharm (Cairo Univ) 2018:1-10. https://doi.org/10.1016/j.bfopcu.2018.04.002.
42. Jain AK, Kakde A, Jain CP, Meena MK, Gaur K. Effect of a combination of surfactant and super disintegrating agent on in vitro disintegration and dissolution release profile of medroxyprogesterone acetate tablet. Int J Pharm Clin Res 2010;2:36-9.
43. Dinge A, Nagarsenker M. Formulation, and evaluation of fast dissolving films for delivery of triclosan to the oral cavity. AAPS J 2008;9:349-56.
44. Mohanachandran PS, Sindhumol PG, Kiran TS. Superdisintegrant: an overview. Int J Pharma Sci Rev Res 2011;6:105-9.
45. Khan WU. Fabrication and evaluation of fast dissolving dosage form of domperidone. Scholar Res Library 2015;7:136-221.